Advertisement

Topics

Sage licenses out depression drug in Asia, adding to cash warchest

05:25 EDT 14 Jun 2018 | BioPharmaDive

Inking a deal with Shionogi for rights to SAGE-217, the biotech will earn $90 million upfront just as it preps for a potential market launch of brexanolone. 

Original Article: Sage licenses out depression drug in Asia, adding to cash warchest

NEXT ARTICLE

More From BioPortfolio on "Sage licenses out depression drug in Asia, adding to cash warchest"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...